Quarterly ResultMay 13, 2026, 04:22 PM
Tango Therapeutics Q1 Net Loss $45.5M; Board Members Resign
AI Summary
Tango Therapeutics reported a Q1 2026 net loss of $45.5 million, or $0.32 per share, with $379.8 million in cash, cash equivalents, and marketable securities, providing a runway into 2028. Concurrently, Alexis Borisy and Kanishka Pothula resigned from the Board of Directors, and Sung Lee was appointed Lead Independent Director and Chairperson of the Compensation Committee. The company also provided positive updates on its vopimetostat clinical program, with initial Phase 1/2 data anticipated in 2026, and announced new key leadership appointments.
Key Highlights
- Q1 2026 net loss was $45.5 million, compared to $39.9 million in Q1 2025.
- Q1 2026 net loss per share was $0.32, compared to $0.36 in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $379.8 million as of March 31, 2026.
- Cash position provides a runway into 2028, beyond anticipated key data inflection points.
- R&D expenses decreased to $33.5 million in Q1 2026 from $36.4 million in Q1 2025.
- G&A expenses increased to $15.2 million in Q1 2026 from $11.5 million in Q1 2025.
- Alexis Borisy and Kanishka Pothula resigned from the Board of Directors.
- Sung Lee appointed Lead Independent Director and Compensation Committee Chairperson.
Price Impact
More from TNGX